Premium
In vitro evaluation of the efficacy of idarubicin in human tumour cells from patients with low‐grade non‐Hodgkin's lymphoma
Author(s) -
Åleskog Anna,
Jonsson Elin,
Larsson Rolf,
Nygren Peter,
Kristensen Jörgen,
Sundström Christer,
Höglund Martin
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03484.x
Subject(s) - idarubicin , medicine , lymphoma , daunorubicin , mitoxantrone , gastroenterology , doxorubicin , anthracycline , chemotherapy , epirubicin , non hodgkin's lymphoma , immunology , cytarabine , cancer , cyclophosphamide , breast cancer
Summary. Evaluating the potential benefit of the new anthracycline, idarubicin (Ida), in lymphoma, 58 tumour samples from patients suffering from low‐grade non‐Hodgkin's lymphoma (L‐NHL), were analysed in vitro for their sensitivity to 0·5 µg/ml Ida. This was compared with the sensitivity to other anthracyclines (0·5 µg/ml), using the fluorometric microculture cytotoxicity assay. A total of 132 samples from patients with acute leukaemia and a cell‐line panel representing different resistance mechanisms was included for comparison. The median cell survival of L‐NHL cells did not differ after exposing the cells to Ida or daunorubicin (Dnr), whereas epirubicin, doxorubicin (Dox) and mitoxantrone (Mitox) were significantly less cytotoxic than Ida ( P < 0·001). The median cell survival in L‐NHL cells did not differ from that of acute leukaemia cells after exposure to 0·5 µg/ml Ida, Dnr, Dox and Mitox. Cells from previously treated patients with L‐NHL had a higher median survival than cells from untreated patients after exposure to all drugs, except for Ida. In samples from previously untreated patients, Spearman rank correlations were high (Rho = 0·81–0·90) between cell survival after exposure to Ida and the other anthracyclines. The same pattern was observed in the cell‐line panel (Rho = 0·78–0·91) ( P < 0·05). In contrast, low correlations (Rho = 0·24–0·42) were observed among samples from previously treated patients. Our results indicate a potential benefit of Ida in previously drug‐treated patients with L‐NHL.